• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国地表水中的人用药品:一项人体健康风险评估。

Human pharmaceuticals in US surface waters: a human health risk assessment.

作者信息

Schwab Bradley W, Hayes Eileen P, Fiori Janice M, Mastrocco Frank J, Roden Nicholas M, Cragin David, Meyerhoff Roger D, D'Aco Vincent J, Anderson Paul D

机构信息

AMEC Earth and Environmental, Suite 1B, Westford, MA 01886, USA.

出版信息

Regul Toxicol Pharmacol. 2005 Aug;42(3):296-312. doi: 10.1016/j.yrtph.2005.05.005.

DOI:10.1016/j.yrtph.2005.05.005
PMID:15979221
Abstract

The detection of low levels of pharmaceuticals in rivers and streams, drinking water, and groundwater has raised questions as to whether these levels may affect human health. This report presents human health risk assessments for 26 active pharmaceutical ingredients (APIs) and/or their metabolites, representing 14 different drug classes, for which environmental monitoring data are available for the United States. Acceptable daily intakes (ADIs) are derived using the considerable data that are available for APIs. The resulting ADIs are designed to protect potentially exposed populations, including sensitive sub-populations. The ADIs are then used to estimate predicted no effect concentrations (PNECs) for two sources of potential human exposure: drinking water and fish ingestion. The PNECs are compared to measured environmental concentrations (MECs) from the published literature and to maximum predicted environmental concentrations (PECs) generated using the PhATE model. The PhATE model predictions are made under conservative assumptions of low river flow and no depletion (i.e., no metabolism, no removal during wastewater or drinking water treatment, and no instream depletion). Ratios of MECs to PNECs are typically very low and consistent with PEC to PNEC ratios. For all 26 compounds, these low ratios indicate that no appreciable human health risk exists from the presence of trace concentrations of these APIs in surface water and drinking water.

摘要

在河流、小溪、饮用水和地下水中检测到低水平的药物,引发了关于这些水平是否会影响人类健康的问题。本报告针对26种活性药物成分(APIs)和/或其代谢物进行了人类健康风险评估,这些成分代表14种不同的药物类别,美国有其环境监测数据。利用可获得的大量关于APIs的数据得出每日可接受摄入量(ADIs)。得出的ADIs旨在保护潜在暴露人群,包括敏感亚人群。然后,ADIs被用于估计两种潜在人类暴露源的预测无效应浓度(PNECs):饮用水和鱼类摄入。将PNECs与已发表文献中的实测环境浓度(MECs)以及使用PhATE模型生成的最大预测环境浓度(PECs)进行比较。PhATE模型预测是在河流低流量和无消耗(即无代谢、废水或饮用水处理过程中无去除以及河流中无消耗)的保守假设下进行的。MECs与PNECs的比值通常非常低,且与PEC与PNEC的比值一致。对于所有26种化合物,这些低比值表明地表水中和饮用水中痕量浓度的这些APIs不会对人类健康造成明显风险。

相似文献

1
Human pharmaceuticals in US surface waters: a human health risk assessment.美国地表水中的人用药品:一项人体健康风险评估。
Regul Toxicol Pharmacol. 2005 Aug;42(3):296-312. doi: 10.1016/j.yrtph.2005.05.005.
2
Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment.水环境中存在的人类用药品对人体健康的风险评估。
Regul Toxicol Pharmacol. 2009 Feb;53(1):39-45. doi: 10.1016/j.yrtph.2008.10.006. Epub 2008 Oct 29.
3
Human health risk assessment of carbamazepine in surface waters of North America and Europe.评估卡马西平对北美洲和欧洲地表水中人体健康的风险
Regul Toxicol Pharmacol. 2010 Apr;56(3):343-51. doi: 10.1016/j.yrtph.2009.10.006. Epub 2009 Oct 31.
4
Screening and human health risk assessment of pharmaceuticals and their transformation products in Dutch surface waters and drinking water.荷兰地表水中的药品及其转化产物的筛选和人体健康风险评估及饮用水
Sci Total Environ. 2012 Jun 15;427-428:70-7. doi: 10.1016/j.scitotenv.2012.04.010. Epub 2012 May 1.
5
Human health risk assessment of pharmaceuticals in water: an uncertainty analysis for meprobamate, carbamazepine, and phenytoin.水中药物的人体健康风险评估:美普他酚、卡马西平和苯妥英的不确定性分析。
Regul Toxicol Pharmacol. 2010 Jul-Aug;57(2-3):146-56. doi: 10.1016/j.yrtph.2010.02.002. Epub 2010 Feb 10.
6
A new risk assessment approach for the prioritization of 500 classical and emerging organic microcontaminants as potential river basin specific pollutants under the European Water Framework Directive.一种新的风险评估方法,用于根据欧洲水框架指令,对 500 种经典和新兴的有机微量污染物进行优先排序,以确定其是否为潜在的流域特有污染物。
Sci Total Environ. 2011 May 1;409(11):2064-77. doi: 10.1016/j.scitotenv.2011.01.054.
7
Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant.传统饮用水处理厂中药物化合物及其他有机废水污染物的持久性
Sci Total Environ. 2004 Aug 15;329(1-3):99-113. doi: 10.1016/j.scitotenv.2004.03.015.
8
Detection of pharmaceutically active compounds in the rivers and tap water of the Madrid Region (Spain) and potential ecotoxicological risk.检测马德里地区(西班牙)河流和自来水中的药物活性化合物及潜在的生态毒理学风险。
Chemosphere. 2011 Sep;84(10):1336-48. doi: 10.1016/j.chemosphere.2011.05.014. Epub 2011 Jun 8.
9
Toxicological relevance of pharmaceuticals in drinking water.饮用水中药物的毒理学相关性。
Environ Sci Technol. 2010 Jul 15;44(14):5619-26. doi: 10.1021/es1004895.
10
An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions.在季节性流感和大流行使用条件下,对污水处理厂和地表水进行的奥司他韦(达菲)环境风险评估。
Ecotoxicol Environ Saf. 2009 Sep;72(6):1625-34. doi: 10.1016/j.ecoenv.2008.09.011. Epub 2009 Jun 26.

引用本文的文献

1
The Occurrence Characteristics and Ecological Risks of Antibiotics in Surface Water and Groundwater of the Huixian Wetland.辉县湿地地表水和地下水中抗生素的赋存特征及生态风险
Toxics. 2025 May 30;13(6):460. doi: 10.3390/toxics13060460.
2
Presence of antibiotics in children's urine: a silent risk beyond drinking water.儿童尿液中抗生素的存在:饮用水之外的潜在风险
Sci Rep. 2025 Apr 9;15(1):12078. doi: 10.1038/s41598-025-94705-8.
3
Occurrence of selected Covid-19 drugs in surface water resources: a review of their sources, pathways, receptors, fate, ecotoxicity, and possible interactions with heavy metals in aquatic ecosystems.
地表水系统中选定的新冠病毒药物的出现:对其来源、途径、受体、命运、生态毒性以及与水生生态系统中重金属可能相互作用的综述。
Environ Geochem Health. 2024 Nov 28;47(1):3. doi: 10.1007/s10653-024-02293-9.
4
Assessing the pharmaceutical residues as hotspots of the main rivers of Catalonia, Spain.评估西班牙加泰罗尼亚主要河流的药物残留热点。
Environ Sci Pollut Res Int. 2024 Jul;31(31):44080-44095. doi: 10.1007/s11356-024-33967-7. Epub 2024 Jun 26.
5
Study on the Mass Spectrometry Cleavage Pattern of Quinolone Antibiotics.喹诺酮类抗生素的质谱裂解模式研究。
ChemistryOpen. 2024 Oct;13(10):e202400061. doi: 10.1002/open.202400061. Epub 2024 Jun 17.
6
Pharmaceutical Residues in Edible Oysters along the Coasts of the East and South China Seas and Associated Health Risks to Humans and Wildlife.《中国东、南海沿海鲜食蚝体内的药物残留及其对人类和野生生物的健康风险》
Environ Sci Technol. 2024 Mar 26;58(12):5512-5523. doi: 10.1021/acs.est.3c10588. Epub 2024 Mar 13.
7
Gaps in Patient Education on Safe Handling and Disposal of Oral Chemotherapy Drugs: A Pilot Prospective Cohort Survey Study.口服化疗药物安全处理与处置患者教育方面的差距:一项前瞻性队列试点调查研究。
J Contemp Pharm Prac. 2022 Spring;70(2):23-33.
8
Human health risk assessment of pharmaceuticals in the European Vecht River.欧洲弗赫特河药物对人类健康风险评估。
Integr Environ Assess Manag. 2022 Nov;18(6):1639-1654. doi: 10.1002/ieam.4588. Epub 2022 Feb 28.
9
An assessment of hospital wastewater and biomedical waste generation, existing legislations, risk assessment, treatment processes, and scenario during COVID-19.对医院废水和生物医疗废物的产生、现有法规、风险评估、处理流程以及新冠疫情期间的情况进行评估。
J Environ Manage. 2022 Apr 15;308:114609. doi: 10.1016/j.jenvman.2022.114609. Epub 2022 Jan 26.
10
Environmental and human health risk assessment of mixture of Covid-19 treating pharmaceutical drugs in environmental waters.环境水体中新冠治疗药物混合物的环境与人类健康风险评估
Sci Total Environ. 2022 Mar 15;812:152485. doi: 10.1016/j.scitotenv.2021.152485. Epub 2021 Dec 20.